Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ascension Rises: Hospital Venture Group Gets More Muscle

This article was originally published in Start Up

Executive Summary

Ascension Health Ventures, already the preeminent hospital-sponsored venture group, secured $200 million from its original sponsor, Ascension Health, as well as two other Catholic-based hospital systems.

You may also be interested in...

Medical Device Market & Industry Briefs, September 2012

Brief summaries of recent medtech market and industry developments. This month we cover results of St. Jude’s FAME II fractional flow reserve trial, a breakthrough technology for treating vascular occlusions, and analysis from START-UP magazine’s second annual Life Science Venture Capital Survey.

Device VCs Choose Flight, And Fight, In Face Of Challenges

The entire venture capital industry is facing difficult times. But few are taking as hard a hit as medical device investors. In our survey of 100 institutional and corporate VCs, 65% of the venture capitalists who said they invest primarily in medical device companies say they’re feeling “negative” about “the current state and future of VC.” Only 17% say they feel positive, with the remainder feeling neutral. Not surprising, device VCs’ worries center around limited partners and the FDA. Limited partners are demanding strong returns before re-upping with new funds, and the FDA, while improving, is holding a firm line in issuing new approvals. Device VCs keep looking for innovative technologies and waiting for opportunities to improve.

START-UP’s 2012 Life Science Venture Capital Survey: Optimism, Capital In Shorter Supply

Our second annual survey of institutional and corporate VCs puts FDA, public markets, and limited partner support high atop a long list of concerns, although the attitude toward regulators is on the mend. A notable number of respondents also say they’ll have to accept lower terms and shrink ambitions as they raise new funds.

Related Content

Related Companies

Related Deals

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts